Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Angel A. Mitma"'
Autor:
David Baker, Milan Bimali, Luis Carrillo, Archana Sachedina, Daisy Alapat, Md Shadiqul Hoque, Mathew Kottarathara, Richa Parikh, Amani Erra, Angel A. Mitma, Pankaj Mathur, Yetunde Ogunsesan, Lakshmi Yarlagadda, Sravani Gundarlapalli, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Guido Tricot, Carolina Schinke
Publikováno v:
Haematologica, Vol 106, Iss 12 (2021)
Externí odkaz:
https://doaj.org/article/9896d7d9005b43379b8cdc6afe8377af
Autor:
Kristin Larsen, Horace Spencer, Meera Mohan, Clyde Bailey, Kerri Hill, Mathew Kottarathara, Richa Parikh, Shadiqul Hoque, Amani Erra, Angel A. Mitma, Pankaj Mathur, Lakshmi Yarlagadda, Sravani Gundarlapalli, Yetunde Ogunsesan, Munawwar Hussain, Nishanth Thalambedu, Jaskirat Sethi, Samer Al Hadidi, Sharmilan Thanendrarajan, Monica Graziutti, Maurizio Zangari, Bart Barlogie, Frits van Rhee, Guido Tricot, Carolina Schinke
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 6, p 1640 (2022)
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for multiple myeloma (MM) patients. Although outpatient ASCT has been shown to be safe and feasible, the procedure is overall rare with most p
Externí odkaz:
https://doaj.org/article/fcd97a41985f4f8fbe151f0de213b088
Autor:
Lakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, Reid D. Landes, Mathew Kottarathara, Yetunde Ogunsesan, Shadiqul Hoque, Angel A. Mitma, Clyde Bailey, Kerri M. Hill, Sharmilan Thanendrarajan, Monica Graziutti, Meera Mohan, Maurizio Zangari, Frits van Rhee, Guido Tricot, Carolina Schinke
Publikováno v:
Cancers, Vol 13, Iss 16, p 4019 (2021)
Daratumumab, a CD38-targeting monoclonal antibody, has significantly improved survival rates in multiple myeloma (MM), yet patients who progress on Daratumumab have dismal clinical outcomes with an overall median of less than 10 months. While emergin
Externí odkaz:
https://doaj.org/article/bc65b9c40ac741dc9c17d6abad2cfd45
Autor:
Amani Erra, Luis Carrillo, Pankaj Mathur, Daisy Alapat, Sravani Gundarlapalli, Sharmilan Thanendrarajan, Lakshmi Yarlagadda, Milan Bimali, Mathew Kottarathara, Maurizio Zangari, Angel A Mitma, Richa Parikh, David Baker, Guido Tricot, Frits van Rhee, Archana Sachedina, Yetunde Ogunsesan, Carolina Schinke, Shadiqul Hoque
Publikováno v:
Haematologica
Not available.
Publikováno v:
Chest. 162:A1825
Publikováno v:
Chest. 162:A1288
Publikováno v:
Transplant Infectious Disease. 23
Hemophagocytic lymphohistiocytosis (HLH) causes multiorgan failure due to the release of multiple cytokines mediating widespread inflammation. We present a patient with multiple myeloma on maintenance chemotherapy with the anti-CD38 monoclonal antibo
Autor:
Sravani Gundarlapalli, Clyde Bailey, Shadiqul Hoque, Reid D. Landes, Angel A Mitma, Guido Tricot, Carolina Schinke, Kerri Hill, Yetunde Ogunsesan, Mathew Kottarathara, Monica Graziutti, Maurizio Zangari, Lakshmi Yarlagadda, Richa Parikh, Frits van Rhee, Sharmilan Thanendrarajan, Meera Mohan
Publikováno v:
Cancers
Volume 13
Issue 16
Cancers, Vol 13, Iss 4019, p 4019 (2021)
Volume 13
Issue 16
Cancers, Vol 13, Iss 4019, p 4019 (2021)
Simple Summary Multiple Myeloma (MM) is the most common cancer of the bone marrow and remains incurable despite advances in novel therapy. The disease course is typically characterized by an initial response pattern to treatment followed by eventual
Autor:
Frits van Rhee, Maurizio Zangari, Phil Farmer, Sharmilan Thanendrarajan, Carolina Schinke, Mathew Kottarathara, Yadav Pandey, Meera Mohan, Angel A Mitma, Guido Tricot, Samantha Kendrick, Richa Parikh, Shadiqul Hoque
Publikováno v:
Blood. 136:11-12
Introduction Novel agents are incorporated into a backbone of multi-agent chemotherapy and tandem transplantation in successive Total Therapy (TT) protocols for multiple myeloma (MM) patients. The TT protocols extend the duration of remission with a
Autor:
Meera Mohan, Sharmilan Thanendrarajan, Clyde Bailey, Carolina Schinke, Monica Grazziutti, Yetunde Ogunsesan, Sravani Gundarlapalli, Shadiqul Hoque, Maurizio Zangari, Frits van Rhee, Mathew Kottarathara, Kerri Hill, Richa Parikh, Angel A Mitma, Lakshmi Yarlagadda, Guido Tricot
Publikováno v:
Journal of Clinical Oncology. 39:e20031-e20031
e20031 Background: The advent of novel therapies has significantly improved outcomes in MM, yet most patients will eventually relapse. Patients progressing on CD38-targeting monoclonal antibodies, proteasome inhibitors (PIs) and IMiDs have dismal out